从静脉输注切换至皮下注射英夫利昔单抗在肥胖的炎症性肠病患者中是安全且可行的：REMSWITCH 研究的事后分析。
Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH Study.
机构信息
Université Clermont Auvergne, Inserm, CHU Clermont-Ferrand, 3iHP, Service d'Hépato-Gastro Entérologie, Clermont-Ferrand, France; Université Clermont Auvergne, 3iHP, Inserm U1071, M2iSH, USC-INRA 2018, Clermont-Ferrand, France.
Université Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
出版信息
Clin Gastroenterol Hepatol. 2024 May;22(5):1127-1129.e2. doi: 10.1016/j.cgh.2023.09.027. Epub 2023 Oct 4.
The REMSWITCH study recently demonstrated that switching from intravenous (IV) to subcutaneous (SC) infliximab (IFX) is feasible and well-accepted leading to a low risk of relapse in patients with inflammatory bowel disease (IBD). Because the doses of IV IFX depend on patients' weight contrary to SC IFX, whether the switch is also feasible in patients with IBD suffering from obesity remains questionable.
REMSWITCH 研究最近表明，将英夫利昔单抗（IFX）从静脉注射（IV）转换为皮下注射（SC）是可行的，并且患者接受度良好，导致炎症性肠病（IBD）患者复发的风险较低。由于 IV IFX 的剂量取决于患者的体重，而 SC IFX 则不然，因此对于患有肥胖症的 IBD 患者，这种转换是否可行仍存在疑问。
Zotero 插件